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the patients is 61 years, with these patients presenting cancer for
an average of 4 years. Eighty-nine percent of the patients use
capecitabine as monotherapy, and the rest use it combined with
injectable treatments. Comparing capecitabine with injectable
regimens, 89% of the studied subjects prefer the oral treatment.
Capecitabine is best evaluated than the injectable treatments in
the attributes: practicability, freedom, quality of life, efﬁcacy and
side effects. Treatments were assessed in a similar way about the
item cost. Approximately third quarters consider capecitabine as
efﬁcient; such rate is slightly higher than the observed for inject-
able chemotherapy: 75% vs. 58%. CONCLUSION: Capecitab-
ine is largely approved by its users, with 89% of them preferring
it in comparison with the injectable treatments. The oral chemo-
therapy has as positive differences, in the perception of its users,
practicability and freedom.
PCN82
PATIENT-REPORTED OUTCOMES IN ELDERLYVS.YOUNG
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OBJECTIVE: Elderly patients are underrepresented in oncology
trials and may be at higher risk of toxicity with less than optimal
quality of life compared with younger patients. The Phase III
TARGET clinical trial showed that sorafenib signiﬁcantly pro-
longed progression-free survival (PFS) compared with placebo
(P < 0.000001) in patients with advanced renal cell carcinoma
(RCC). This retrospective analysis of sorafenib in advanced
RCC patients from the pivotal TARGET trial compared patient
reported outcomes (PRO) in young and elderly patients.
METHODS: This subgroup analysis examined the PRO in
elderly (>=70 years of age) and young patients (<70 years of age)
for sorafenib and placebo. PRO was assessed at baseline and day
1 of each cycle using Functional Assessment of Cancer Therapy-
General (FACT-G) and FACT-Kidney Cancer Symptom Index
(FKSI). Descriptive statistics compared the proportion of patients
with a clinically meaningful change (4 point change) in total
scores of FKSI and Physical Well Being (PWB) from baseline.
Time to health status deterioration (4 point drop in total FKSI
scores or PWB scores of FACT-G) was assessed using Cox-
proportional Hazards model. RESULTS: A greater proportion of
patients in the sorafenib-treated group had improved or stable
symptom response and physical functioning in later cycles of
treatment, irrespective of age. Sorafenib delayed median time to
health status deterioration (as measured by FKSI questionnaire)
compared to placebo in elderly patients (121 days vs. 85 days)
The median time to health status deterioration as measured by
PWB domain of FACT-G was also longer for sorafenib compared
to placebo among elderly patients (126 vs. 84 days). A similar
trend was observed in younger patients. CONCLUSION: When
compared with placebo, elderly patients with advanced RCC
receiving sorafenib had PROs similar to those of young patients
receiving the same treatment, with both groups maintaining their
quality of life longer on sorafenib.
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OBJECTIVE: According to INCA (National Cancer Institute of
Brazil) estimates, colorectal cancer is the ﬁfth most common type
of cancer in the population; otherwise, it is the thirrd leading type
of tumor to cause death. The objective of this research is to assess
the knowledge of the Brazilian population about colorectal
cancer, its risks and diagnosis. METHODS: Quantitative study
performed through personal and individual interviews. A repre-
sentative sample of the study population (N = 600) was used.
People over 30 years old were interviewed. A 10-item structured
questionnaire was used. RESULTS: The study showed that 70%
of the population consider themselves as informed about cancer.
When asked about which would be the 3 most common types of
cancer, the main answers given were: 66% breast, 46% cervix,
42% prostate, 16% skin, and 15% lung. The colorectal cancer
was not mentioned by any subject in this question. Fifty-seven
percent of the population had never heard about colorectal
cancer. Among the 43% who had already heard about this type
of tumor, 76% didn’t know what were the symptoms and pre-
vention measures for this disease. Only 18% of the subjects over
50 years old have already undergone diagnostic tests for colorec-
tal cancer. CONCLUSION: Colorectal cancer is known for only
43% of the Brazilian population, which does not identify it as
one of the main tumors causing death in the country. In addition,
76% of the subjects who have already heard about this type of
cancer do not know the diagnostic and prevention methods for
this tumor. Only 18% of the population over 50 years old has
already undergone diagnostic tests for this type of cancer. These
results show that information campaigns about cancer could
render a better knowledge of the disease, which could result, in
the future, in early diagnosis, enabling a higher chance of cure
for patients.
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OBJECTIVE: Certain recent policy changes have mandated
ESA initiation at Hb < 10 g/dL. Real world clinical and eco-
nomic outcomes data associated with this change have not
been reported for the two FDA-approved ESAs for this popu-
lation [epoetin alfa (EPO) and darbepoetin alfa (DARB)].
METHODS: Data drawn between 12/03–11/07 from 55 U.S.
oncology clinics from the Dosing and Outcomes Study of
Erythropoietic Stimulating Therapies (D.O.S.E.) registry were
assessed. Patients were included if they were initiated on ESAs
with a BL Hb < 10 g/dL, age 18 years, and received 2 doses
of either EPO or DARB. Outcomes assessed included transfu-
sion utilization, Hb at Weeks 4, 8, 12 and 16 after ESA initia-
tion, and cumulative ESA doses with associated cost (based on
11/2007 wholesale acquisition cost). RESULTS: A total of 384
patients (168 EPO, 216 DARB) were identiﬁed. BL character-
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istics were similar between treatment groups with regard to
age, weight, cancer type and Hb. The proportion of patients
transfused was similar between groups (~30%). Mean Hb
values were consistently higher in the EPO group compared to
the DARB group at Weeks 4, 8, 12, and 16. A repeated mea-
sures model showed a signiﬁcant Hb increase from BL at each
timepoint assessed in both groups as well as a signiﬁcant dif-
ference between the two groups. Mean cumulative administered
dose was 342,959 Units for EPO and 1239 mcg for DARB with
overall ESA drug cost signiﬁcantly lower in the EPO group
compared to the DARB group (EPO $4503, DARB $5669
p < 0.001). CONCLUSION: In patients with Hb < 10 g/dL
prior to ESA initiation, mean Hb levels were higher in the EPO
group than the DARB group throughout the study, with ESA
drug costs 21% lower in the EPO group than the DARB group.
Such ﬁndings inform decision-makers on ESA-associated
outcomes based on initiation as imposed in certain coverage
policies.
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OBJECTIVE: The National Cancer Institute indicates surgery,
chemotherapy, and/or radiation treatments in colorectal cancer
(CRC). Data on the effect of age and place of residence on
accessing CRC treatments in the Midwest region of United States
is limited. Therefore, using Nebraska Cancer Registry we tested
the hypothesis that CRC patients’ residence-county and age
would be associated with receipt of surgery, radiation, and che-
motherapy treatments. METHODS: In a retrospective study, we
examined treatments of 6813 CRC patients identiﬁed by incident
ICD-O CM codes between January 1998, and December 2003
from the Nebraska Cancer Registry data. In multivariate logistic
regression analyses, we studied the association of age and the
year 2003 Urban Inﬂuence Code based residence-county with
each of the three CRC treatments. RESULTS: After adjusting
for patient’s demographics, insurance payer, county-speciﬁc
provider-to-population ratio, and stage and anatomical site,
CRC patients living in small urban counties were more likely to
receive chemotherapy than were those living in rural counties
(adjusted Odds-Ratio, OR, 1.53; 95% conﬁdence-interval, CI:
1.25–1.88, p < 0.001). However, there were no signiﬁcant rural-
urban differences in receiving any CRC treatment. Compared
with 19-to-64-year-olds, patients aged 75 years and older with
local CRC stage were less likely to receive surgery (OR, 0.22;
95% CI: 0.07–0.76, p < 0.001), patients aged 75 years and older
were less likely to receive radiation (OR, 0.36; 95% CI: 0.24–
0.55, p < 0.0001), and patients aged 75 years and older were less
likely to receive chemotherapy (OR, 0.21; 95% CI: 0.16–0.27,
p < 0.0001). CONCLUSION: Nebraska CRC patients living in
rural counties were less likely to receive chemotherapy than were
those living in small urban counties. Elderly CRC patients were
less likely to receive surgery, radiation, and chemotherapy treat-
ments. Despite limitations of registry data, these ﬁndings warrant
the attention of decision-makers to age and geographic access
issues in planning future delivery of CRC treatments.
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OBJECTIVE: To assess current real-world utilization of ESAs
in patients with MDS, recent epoetin alfa (EPO) and darbepo-
etin alfa (DARB) dosing patterns and ESA treatment costs were
examined. METHODS: A retrospective analysis was conducted
using medical claims from approximately 45 health plans
nationwide during the period of Janaury 2004–June 2007.
Patients included in the study were 18 years old, had 1
claim for MDS (ICD-9 code: 238.7) prior to initiating ESA
therapy, and were newly initiated on EPO or DARB with 2
doses of either drug during the treatment period. Patients with
cancer before initiating ESA treatment for MDS were excluded.
The study period terminated with the last ESA treatment dose,
end of data availability, initial AML diagnosis, or initial stem
cell transplant, whichever occurred ﬁrst. Mean cumulative ESA
dose was used to calculate ESA cost (based on October 2007
WAC) and dose ratio (Units EPO : mcg DARB). RESULTS: The
study population consisted of 275 patients who received EPO
and 155 patients who received DARB. Mean age and gender
distribution was similar between the two groups. Mean treat-
ment duration was also similar for both groups (EPO: 75 days;
DARB: 71 days; p = 0.638). The mean cumulative ESA dose
administered was 374,415 Units for EPO and 1475 mcg for the
DARB group, corresponding to a dose ratio of 254:1 (Units
EPO: mcg DARB). Based on these doses, ESA cost was $2139
(31%) less for EPO than for DARB (EPO: $4688; DARB:
$6827; p = 0.010). CONCLUSION: These real-life clinical
practice ﬁndings in the MDS population show signiﬁcantly
lower drug cost in the EPO group compared to the DARB
group and a dose ratio of 254:1 (Units EPO : mcg DARB)
between the two agents.
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OBJECTIVE: To evaluate the presence of pharmacoeconomic
messages in the US, France, Germany, Italy, Spain, and UK for
ten representative oncology products (Alimta, Avastin, Gemzar,
Herceptin, Neulasta, Novantrone, Sutent, Tarceva, Taxotere,
and Velcade). METHODS: This qualitative assessment covered
the following data sources: 1) Government websites (Canadian
Agency for Drugs and Technologies in Health, National Insti-
tute for Health and Clinical Excellence, Institut für Qualität
und Wirtschaftlichkeit im Gesundheitswesen, La Haute
Autorité de santé, and Cochrane Reviews); 2) company spon-
sored product websites; 3) FDA and EMEA products labels;
and 4) promotional materials (detail aid brochures, direct mail,
and professional journal/newsletter ads). These data sources
were searched for relevant pharmacoeconomic messaging
including statements regarding cost, QoL, utility, patient pre-
ference, etc. RESULTS: While health technology assessments
have a clear impact on market access, speciﬁc examples of
pharmacoeconomic data in promotional messaging was limited.
Pharmacoeconomic messages, with particular focus on QoL,
were more prominent in promotional materials of oncology
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